杭州知兴制药

Zhixing Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of next-generation small molecule therapeutics for metabolic and inflammatory diseases. The company's lead program, ZX-101, is a potent and highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Founded in 2021 by industry veterans with extensive experience in medicinal chemistry, Zhixing leverages its internal R&D capabilities to target high-value biological pathways. The company is backed by prominent venture capital firms and aims to provide innovative, effective treatments for patients with significant unmet medical needs in the global metabolic health market.